Tenax Therapeutics, Inc. (Nasdaq: TENX) announced the pricing of an underwritten offering for gross proceeds of approximately $10 million, prior ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE